| Trial ID: | L2599 |
| Source ID: | NCT05762744
|
| Associated Drug: |
Exenatide Injection
|
| Title: |
Pharmacogenomics of GLP1 Receptor Agonists
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: Exenatide Injection|DRUG: Saline injection
|
| Outcome Measures: |
Primary: First phase insulin secretion (placebo), The area under the curve for plasma insulin levels during a frequently sampled intravenous glucose tolerance test after participants received saline, 0-10 minutes|First phase insulin secretion (exenatide), The area under the curve for plasma insulin levels during a frequently sampled intravenous glucose tolerance test after participants received exenatide, 0-10 minutes|Exenatide effect on first phase insulin secretion, The difference between the logarithm of first phase insulin secretion (exenatide) minus the logarithm of the first phase insulin secretion (placebo), 0-10 minutes|glucose disappearance rate (placebo), The slope of the line plotting the logarithm of glucose concentrations as a function of time during the placebo frequently sampled intravenous glucose tolerance test, 25-50 minutes|glucose disappearance rate (exenatide), The slope of the line plotting the logarithm of glucose concentrations as a function of time during the exenatide frequently sampled intravenous glucose tolerance test, 25-50 minutes|Exenatide effect on glucose disappearance rate, The difference between glucose disappearance rate (exenatide) minus glucose disappearance rate (placebo), 25-50 minutes |
|
| Sponsor/Collaborators: |
Sponsor: University of Maryland, Baltimore
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
78
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2016-06-01
|
| Completion Date: |
2022-10-31
|
| Results First Posted: |
|
| Last Update Posted: |
2023-03-10
|
| Locations: |
Amish Research Clinic, Lancaster, Pennsylvania, 17602, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT05762744
|
